Citicoline vs Noopept
Citicoline supplies building blocks for acetylcholine and cell membranes and has been tested in large stroke and cognition trials; noopept is a synthetic compound registered in Russia, with a smaller clinical literature.
Citicoline
A naturally occurring intermediate in phosphatidylcholine synthesis, studied as a neuroprotective and cognitive compound.
BEST STUDIED FOR
Nootropic & neuro
Read the cited profile →
Noopept
A proline-containing dipeptide nootropic developed in Russia as a piracetam analogue, whose metabolite resembles an endogenous neuropeptide.
BEST STUDIED FOR
Nootropic & neuro
Read the cited profile →
SIDE BY SIDE
| Citicoline | Noopept | |
|---|---|---|
| The key difference | Choline and cytidine donor | Russian prolyl-dipeptide nootropic |
| Class | Nootropic & neuro | Nootropic & neuro |
| Mechanism | Citicoline supplies choline and cytidine for neuronal membrane phospholipids and influences acetylcholine, dopamine and glutamate systems. | Noopept is metabolised to cyclo-L-prolylglycine, an endogenous cyclic dipeptide. |
| Status | Registered medicine in several countries (stroke, cognitive impairment) and a supplement elsewhere; evidence in stroke is debated. | Registered as a medicine in Russia; unapproved elsewhere. It has been found as an undeclared ingredient in US "cognitive" supplements. |
| Reported safety signals | Reviews describe a favourable safety profile. | Human data are limited to Russian clinical use; an FDA-related analysis found it among unapproved drugs in supplements, raising quality and dose concerns. |
| A key study | A comprehensive pharmacological and clinical review of citicoline. (Rev Neurol 2022, PMID 36544369) | Identified noopept’s main brain metabolite as resembling the endogenous peptide cyclo-L-prolylglycine. (Eur J Drug Metab Pharmacokinet 1997, PMID 9358206) |
WHEN TO RESEARCH WHICH
Citicoline has the broader international trial base; noopept the regional clinical use. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [Citicoline] Citicoline: pharmacological and clinical review, 2022 update — Rev Neurol 2022. PMID 36544369
- [Citicoline] Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial — J Nutr 2021. PMID 33978188
- [Citicoline] Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis — Nutrients 2023. PMID 36678257
- [Noopept] The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine — Eur J Drug Metab Pharmacokinet 1997. PMID 9358206
- [Noopept] Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model — Behav Pharmacol 1999. PMID 10780261
- [Noopept] Five Unapproved Drugs Found in Cognitive Enhancement Supplements — Neurol Clin Pract 2021. PMID 34484905
FREQUENTLY ASKED
What is the difference between Citicoline and Noopept?
Citicoline supplies building blocks for acetylcholine and cell membranes and has been tested in large stroke and cognition trials; noopept is a synthetic compound registered in Russia, with a smaller clinical literature.
What is the regulatory status of Citicoline and Noopept?
Citicoline: Registered medicine in several countries (stroke, cognitive impairment) and a supplement elsewhere; evidence in stroke is debated. Noopept: Registered as a medicine in Russia; unapproved elsewhere. It has been found as an undeclared ingredient in US "cognitive" supplements.
What safety signals have been reported?
Citicoline: Reviews describe a favourable safety profile. Noopept: Human data are limited to Russian clinical use; an FDA-related analysis found it among unapproved drugs in supplements, raising quality and dose concerns.
Which studies is this comparison based on?
For Citicoline: “Citicoline: pharmacological and clinical review, 2022 update” (PMID 36544369); “Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial” (PMID 33978188); “Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis” (PMID 36678257). For Noopept: “The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine” (PMID 9358206); “Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model” (PMID 10780261); “Five Unapproved Drugs Found in Cognitive Enhancement Supplements” (PMID 34484905).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use